Compounds of the formula: ##STR1## wherein R1 represents a lower alkyl (C1-C6) substituent which may be straight or branched; R2 represents an aryl substituent of the formula: ##STR2## and Q, V, W, X, Y and Z are as set forth in the accompanying specification, are useful in prophylaxis of influenza virus infection.
This is a continuation of co-pending U.S. application Ser. No. 08/858,649, filed May 19, 1997, which is a continuation-in-part of U.S. application Ser. No. 08/681,289, filed Jul. 22, 1996 (now abandoned).
Compounds of the formula: ##STR1## wherein R1 represents a lower alkyl (C1-C6) substituent which may be straight or branched; R2 represents an aryl substituent of the formula: ##STR2## and Q, V, W, X, Y and Z are as set forth in the accompanying specification, are useful in prophylaxis of influenza virus infection.
A compound produced by the process comprising the step of reacting a starting compound of the formula: ##STR1## with FeCl.sub.3 in the presence of acetic acid, wherein the reaction mixture is heated and the temperature of the reaction mixture is about 85.degree. C.to about reflux temperature, R.sub.1 and R.sub.2 in the above formula being as defined in the present specification.
Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.
Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.
